Embecta Corp. (EMBC)
- Previous Close
10.40 - Open
10.40 - Bid 10.28 x 200
- Ask 10.32 x 200
- Day's Range
10.29 - 10.58 - 52 Week Range
9.93 - 32.00 - Volume
250,935 - Avg. Volume
433,509 - Market Cap (intraday)
593.638M - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
10.74 - EPS (TTM)
0.96 - Earnings Date May 9, 2024
- Forward Dividend & Yield 0.60 (5.82%)
- Ex-Dividend Date Feb 27, 2024
- 1y Target Est
16.50
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
www.embecta.com2,200
Full Time Employees
September 30
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: EMBC
Performance Overview: EMBC
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EMBC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EMBC
Valuation Measures
Market Cap
593.64M
Enterprise Value
1.93B
Trailing P/E
10.74
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.53
Price/Book (mrq)
--
Enterprise Value/Revenue
1.72
Enterprise Value/EBITDA
9.31
Financial Highlights
Profitability and Income Statement
Profit Margin
4.93%
Return on Assets (ttm)
10.21%
Return on Equity (ttm)
--
Revenue (ttm)
1.12B
Net Income Avi to Common (ttm)
55.3M
Diluted EPS (ttm)
0.96
Balance Sheet and Cash Flow
Total Cash (mrq)
298.7M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
3.96M
Research Analysis: EMBC
Company Insights: EMBC
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: EMBC
EMBC: Raising target price to $12.00
EMBECTA CORP has an Investment Rating of BUY; a target price of $12.000000; an Industry Subrating of Low; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetEMBC: Lowering target price to $11.00
EMBECTA CORP has an Investment Rating of BUY; a target price of $11.000000; an Industry Subrating of Low; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetEMBC: Lowering target price to $13.00
EMBECTA CORP has an Investment Rating of BUY; a target price of $13.000000; an Industry Subrating of Low; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice TargetEMBC: What does Argus have to say about EMBC?
EMBECTA CORP has an Investment Rating of BUY; a target price of $14.000000; an Industry Subrating of Low; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice Target